These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 33516602)

  • 1. US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Dal-Ré R
    Vaccine; 2021 Feb; 39(8):1180-1182. PubMed ID: 33516602
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
    Joffe S
    JAMA; 2021 Jan; 325(3):221-222. PubMed ID: 33315069
    [No Abstract]   [Full Text] [Related]  

  • 3. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
    Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 69(5152):1653-1656. PubMed ID: 33382675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine.
    Dal-Ré R; Caplan AL; Gluud C; Porcher R
    Ann Intern Med; 2021 Feb; 174(2):258-260. PubMed ID: 33216636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA authorizes Pfizer-BioNTech COVID-19 vaccine.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):1-2. PubMed ID: 33646996
    [No Abstract]   [Full Text] [Related]  

  • 6. An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19.
    Kesselheim AS; Darrow JJ; Kulldorff M; Brown BL; Mitra-Majumdar M; Lee CC; Moneer O; Avorn J
    Health Aff (Millwood); 2021 Jan; 40(1):25-32. PubMed ID: 33211535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.
    Krause PR; Gruber MF
    N Engl J Med; 2020 Nov; 383(19):e107. PubMed ID: 33064383
    [No Abstract]   [Full Text] [Related]  

  • 9. Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Dal-Ré R; Orenstein W; Caplan AL
    Nat Med; 2021 Jun; 27(6):938. PubMed ID: 33903751
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.
    Pai SM; Othman AA; Rusch L; Masters JC; Greene D; Rogge M; Gries JM; Clementi W; Kumar P; Younis I; Salem AH; Gaynes BI; Pastino G; Derendorf H;
    J Clin Pharmacol; 2021 Mar; 61(3):277-279. PubMed ID: 33274473
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
    Thomson K; Nachlis H
    JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
    [No Abstract]   [Full Text] [Related]  

  • 13. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
    Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC
    Drug Discov Today; 2021 Feb; 26(2):593-603. PubMed ID: 33253920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
    Singh JA; Upshur REG
    Lancet Infect Dis; 2021 Apr; 21(4):e103-e109. PubMed ID: 33306980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA authorizes Johnson & Johnson COVID-19 vaccine.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):41-42. PubMed ID: 33976088
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA authorizes first single-shot COVID-19 vaccine.
    Mullard A
    Nat Rev Drug Discov; 2021 Apr; 20(4):251. PubMed ID: 33707753
    [No Abstract]   [Full Text] [Related]  

  • 17. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.
    Follmann D; Fintzi J; Fay MP; Janes HE; Baden LR; El Sahly HM; Fleming TR; Mehrotra DV; Carpp LN; Juraska M; Benkeser D; Donnell D; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Luedtke A; Carone M; Nason M; Vandebosch A; Zhou H; Cho I; Gabriel E; Kublin JG; Cohen MS; Corey L; Gilbert PB; Neuzil KM
    Ann Intern Med; 2021 Aug; 174(8):1118-1125. PubMed ID: 33844575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
    Powell J; Piszczatoski CR
    Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.